| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2007, p. 2179-2184, Vol. 51, No. 6
0066-4804/07/$08.00+0 doi:10.1128/AAC.01600-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Stéphane Corvec,1,2,
Melina Rapoport,3
Pauline Mugnier,1
Alejandro Petroni,3
Fernando Pasteran,3
Diego Faccone,3
Marcelo Galas,3
Henri Drugeon,2
Vincent Cattoir,1 and
Patrice Nordmann1*
Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine Paris-Sud, Université Paris XI, K.-Bicêtre, Paris, France,1 Laboratoire de Bactériologie-Virologie, Hygiène Hospitalière, CHU, Nantes, France,2 Servicio Antimicrobianos, Depertamento Bacteriologia, Instituto Nacional de Enfermedades Infecciosas-ANLIS Carlos G. Malbran, Ciudad Autonoma de Buenos Aires, Argentina3
Received 22 December 2006/ Returned for modification 15 February 2007/ Accepted 23 March 2007
By studying the ß-lactamase content of several Acinetobacter spp. isolates from Argentina, producing the expanded-spectrum ß-lactamases (ESBL) VEB-1a or PER-2, a novel Ambler class A ß-lactamase gene was identified. It encoded the narrow-spectrum ß-lactamase SCO-1, whose activity was inhibited by clavulanic acid. SCO-1 hydrolyzes penicillins at a high level and cephalosporins and carbapenems at a very low level. ß-Lactamase SCO-1 was identified from unrelated VEB-1a-positive or PER-2-positive Acinetobacter spp. isolates recovered from three hospitals. The blaSCO-1 gene was apparently located on a plasmid of ca. 150 kb from all cases but was not associated with any ESBL-encoding gene. The G+C content of the blaSCO gene was 52%, a value that does not correspond to that of the A. baumannii genome (39%). ß-Lactamase SCO-1 shares 47% amino acid identity with CARB-5 and ca. 40% with the enzymes TEM, SHV, and CTX-M. A gene encoding a putative resolvase was identified downstream of the blaSCO-1 gene, but its precise way of acquisition remains to be determined.
Published ahead of print on 9 April 2007.
L.P. and S.C. contributed equally to this work.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |